Ad
related to: lenvatinib clinical trials
Search results
Results from the WOW.Com Content Network
A phase I clinical trial in cancer patients was performed in 2006. [11] A phase III trial treating thyroid cancer patients started in March 2011. [12] Lenvatinib was granted orphan drug status for treatment of various types of thyroid cancer that do not respond to radioiodine in the US and Japan in 2012 and in Europe in 2013. [13]
Eisai/Merck's (MRK) sNDA for cancer drug, lenvatinib, seeking approval for first-line treatment of HCC gets a three-month extension from the FDA.
The DRKS is an open access, free of charge online register for clinical trials and is available both in English and German. DRKS is part of the WHO's ICTRP. The DRKS works with two partner registries in Germany, DeReG (German Registry for Somatic Gene-Transfer Trials) and Clinical Trial Registry of the University Medical Center Freiburg. [4]
Toni K. Choueiri is a Lebanese American medical oncologist and researcher. He is the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School and director of the Lank Center for Genitourinary Oncology at the Dana–Farber Cancer Institute.
Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. [1] It is a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division.
Various radiological clinical criteria, including the thyroid imaging reporting and data system (TI-RADs) score, are used to characterize the risk of malignancy. [24] TI-RADS developed by the American College of Radiology (ACR) guides clinicians in deciding which nodules require fine-needle aspiration cytology (FNAC) and in planning follow-up.
AllTrials (sometimes called All Trials or AllTrials.net) is a project advocating that clinical research adopt the principles of open research.The project summarizes itself as "All trials registered, all results reported": that is, all clinical trials should be listed in a clinical trials registry, and their results should always be shared as open data.
Clinical trial number NCT04065399 for "A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)" at ClinicalTrials.gov Clinical trial number NCT05918913 for "Expanded Access Program for Revumenib" at ClinicalTrials.gov
Ad
related to: lenvatinib clinical trials